The U.S. unit of Indian drugmaker Dr. Reddy’s Laboratories is recalling 331,590 bottles of cinacalcet tablets used to treat hyperparathyroidism due to the presence of a known carcinogen. | The U.S.
Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets in the US due to manufacturing issues. The ...
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
During the initial titration phase of up to 16 weeks, patients received increasing dosages of cinacalcet until the serum calcium concentration was <2.5 mmol/l, the highest possible dosage was ...
Stocks to watch on Monday, November 4, 2024: Indian bourses are preparing for a negative start on Monday, indicated GIFT ...
Cinacalcet (Sensipar ® /Mimpara ®, Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is ...
Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Until now, no randomized, placebo-controlled, long-term trial has tested this drug in individuals ...